Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study.
injectables
neuromodulators
neurotoxin
surgical scars
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
25
09
2023
revised:
21
10
2023
accepted:
28
10
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoNT-A in scar prevention. Fifteen patients who had undergone subcutaneous mastectomy were included. At 14 days post-surgery, either incoBoNT-A or a placebo was injected into the scar on each side. The primary outcome assessment measured the scar's severity using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). The secondary outcome assessment evaluated the scar's color using a standard measurement device. Outcome assessments were conducted until 6 months post-surgery. There were significantly lower VSS scores in the BoNT-A group compared to the placebo at the end of the study (7.43 ± 0.26 vs. 8.82 ± 0.26, BoNT-A has demonstrated effectiveness in scar prevention by reducing the severity of postoperative scar formation and improving overall scar appearance.
Sections du résumé
BACKGROUND
BACKGROUND
Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoNT-A in scar prevention.
METHODS
METHODS
Fifteen patients who had undergone subcutaneous mastectomy were included. At 14 days post-surgery, either incoBoNT-A or a placebo was injected into the scar on each side. The primary outcome assessment measured the scar's severity using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). The secondary outcome assessment evaluated the scar's color using a standard measurement device. Outcome assessments were conducted until 6 months post-surgery.
RESULTS
RESULTS
There were significantly lower VSS scores in the BoNT-A group compared to the placebo at the end of the study (7.43 ± 0.26 vs. 8.82 ± 0.26,
CONCLUSION
CONCLUSIONS
BoNT-A has demonstrated effectiveness in scar prevention by reducing the severity of postoperative scar formation and improving overall scar appearance.
Identifiants
pubmed: 37999499
pii: toxins15110636
doi: 10.3390/toxins15110636
pmc: PMC10680993
pii:
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Plast Reconstr Surg. 2019 Feb;143(2):375e-381e
pubmed: 30688903
J Craniofac Surg. 2020 Mar/Apr;31(2):440-443
pubmed: 31977704
Brain Res Bull. 2017 Jan;128:68-75
pubmed: 27693649
J Plast Surg Hand Surg. 2012 Apr;46(2):95-101
pubmed: 22471257
Arch Facial Plast Surg. 2001 Jul-Sep;3(3):165-9
pubmed: 11497500
Ann Plast Surg. 2016 Nov;77(5):535-538
pubmed: 26418784
Medicine (Baltimore). 2019 Aug;98(34):e16952
pubmed: 31441893
Facial Plast Surg Clin North Am. 2007 Aug;15(3):353-60, vi-vii
pubmed: 17658431
J Sex Med. 2012 Dec;9(12):3148-53
pubmed: 23035854
Cult Health Sex. 2017 Jan;19(1):64-75
pubmed: 27300085
J Sex Med. 2016 Nov;13(11):1778-1786
pubmed: 27667355
Br J Dermatol. 2018 May;178(5):1011-1019
pubmed: 29086923
Wound Repair Regen. 2015 Jul-Aug;23(4):531-7
pubmed: 25857804
JAMA Surg. 2018 Jul 1;153(7):609-616
pubmed: 29490365
Int J Mol Med. 2019 Aug;44(2):661-671
pubmed: 31173164
J Cutan Med Surg. 2020 Nov/Dec;24(6):608-618
pubmed: 32608997
Am J Phys Anthropol. 2000 May;112(1):17-27
pubmed: 10766940
Clin Exp Otorhinolaryngol. 2009 Mar;2(1):20-7
pubmed: 19434287
J Cell Mol Med. 2021 Oct;25(19):9402-9410
pubmed: 34472704
Arch Dermatol Res. 2006 Apr;297(10):433-8
pubmed: 16528552
Plast Reconstr Surg. 2006 Sep 15;118(4):909-918
pubmed: 16980850
Clin Dermatol. 1995 Jul-Aug;13(4):369-73
pubmed: 8665445
Plast Reconstr Surg. 2018 Mar;141(3):646-650
pubmed: 29481395
Lancet. 2016 Jul 23;388(10042):412-436
pubmed: 27323919
J Plast Reconstr Aesthet Surg. 2014 Aug;67(8):1017-25
pubmed: 24888226
PLoS One. 2014 Dec 26;9(12):e115690
pubmed: 25541942
Plast Reconstr Surg. 2005 Aug;116(2):514-22
pubmed: 16079683
Aesthetic Plast Surg. 2018 Oct;42(5):1364-1369
pubmed: 30019241
Arch Plast Surg. 2019 Sep;46(5):433-440
pubmed: 31550748
Mol Cell Biochem. 2012 Feb;361(1-2):161-8
pubmed: 21989717
Plast Reconstr Surg. 2000 May;105(6):1948-53; discussion 1954-5
pubmed: 10839391
J Plast Reconstr Aesthet Surg. 2013 Feb;66(2):209-14
pubmed: 23102873
JAMA Facial Plast Surg. 2019 Sep 01;21(5):452-457
pubmed: 31436786
Scand J Surg. 2017 Mar;106(1):74-79
pubmed: 27107053
Aesthetic Plast Surg. 2020 Dec;44(6):2270-2276
pubmed: 32813130
Dermatol Surg. 2017 Jan;43 Suppl 1:S3-S18
pubmed: 27347634
Clin Epidemiol. 2012;4:187-91
pubmed: 22879780
Lancet. 2016 Jul 23;388(10042):390-400
pubmed: 27323925
Ann R Coll Surg Engl. 1985 Jul;67(4):238-40
pubmed: 4037635
J Plast Reconstr Aesthet Surg. 2009 Jul;62(7):906-13
pubmed: 18436495
Aesthetic Plast Surg. 2018 Apr;42(2):530-537
pubmed: 29214336
Plast Reconstr Surg Glob Open. 2018 Apr 16;6(4):e1738
pubmed: 29876180